Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.

被引：0
|
作者：
Nikitas, John
Lam, Ethan C.
Booker, Kiara M.
Fendler, Wolfgang P.
Eiber, Matthias
Hadaschik, Boris A.
Herrmann, Ken
Hirmas, Nader
Lanzafame, Helena
Stuschke, Martin
Czernin, Johannes
Steinberg, Michael L.
Nickols, Nicholas George
Kishan, Amar Upadhyaya
Calais, Jeremie
机构：
[1] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Ahmanson Translat Theranost Div, Los Angeles, CA USA
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Nucl Med, Essen, Germany
[4] Tech Univ Munich, Dept Nucl Med, Munich, Germany
[5] Univ Duisburg Essen, Dept Urol, Essen, Germany
[6] Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[7] Univ Duisburg Essen, Dept Nucl Med, Essen, Germany
[8] Univ Duisburg Essen, Univ Med Essen, Dept Radiotherapy, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
613-615-646-3281-7408-2399; 261-137; 283-183-180; 613-545; 261-436-2730; 14; 6; 3; 3617; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.291
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：291 / 291
页数：1
相关论文
共 50 条
  • [31] PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review
    Petersen, Lars J.
    Zacho, Helle D.
    CANCER IMAGING, 2020, 20 (01)
  • [32] Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
    Guler, Ozan Cem
    Onal, Cem
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 164 - 165
  • [33] PSMA-targeted PET with [68Ga]Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer.
    Bahler, Clinton
    Tann, Mark
    Green, Mark
    Hutchins, Gary
    Mathias, Carla
    Whaley, Rumeal
    Cheng, Liang
    Alexoff, David
    Kung, Hank
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial
    Nabid, Abdenour
    Carrier, Nathalie
    Vigneault, Eric
    Van Nguyen, Thu
    Vavassis, Peter
    Brassrard, Marc-Andre
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Wilke, Derek
    Souhami, Luis
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : 732 - 740
  • [35] Randomized phase II trial of IGRT with or without HDR boost in intermediate-risk prostate cancer
    Vigneault, E.
    Morton, G.
    Perulekar, W.
    Niazi, T.
    Springer, G.
    Barkati, M.
    Chung, P.
    Koll, W.
    Kamran, A.
    Montreal, M.
    Ding, K.
    Loblaw, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S975 - S976
  • [36] Survival outcomes in men with unfavorable intermediate-risk and high-risk prostate cancer treated with prostate-only versus whole pelvic radiation therapy.
    Andruska, Neal
    Fischer-Valuck, Benjamin Walker
    Diaz, Elizabeth Juarez
    Agabalogun, Temitope
    Brenneman, Randall
    Gay, Hiram Alberto
    Michalski, Jeff M.
    Baumann, Brian C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] 68 Ga-PSMA PET/CT for preoperative lymph nosde staging of high-risk prostate cancer.
    Heidenreich, Axel
    Schmautz, Maximilian
    Pfister, David A.
    Hartmann, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [38] PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial
    Petit C.
    Delouya G.
    Taussky D.
    Barkati M.
    Lambert C.
    Beauchemin M.-C.
    Clavel S.
    Mok G.
    Paré A.-S.G.
    Nguyen T.-V.
    Duplan D.
    Keu K.V.
    Saad F.
    Juneau D.
    Ménard C.
    International Journal of Radiation Oncology Biology Physics, 2023, 116 (04): : 779 - 787
  • [39] PSMA-density predicts pathological and oncological outcomes in patients submitted to 18F-PSMA-1007 PET/CT for the primary staging of unfavorable intermediate and high-risk prostate cancer
    Donegani, M.
    Ambrosini, F.
    Mantica, G.
    Piol, N.
    Miceli, A.
    D'Amico, F.
    Riondato, M.
    Di Raimondo, T.
    Lanfranchi, F.
    Raffa, S.
    Chiola, S.
    Spina, B.
    Suardi, N.
    Morbelli, S.
    Borghesi, M.
    Nozza, P.
    Fiocca, R.
    Sambuceti, G.
    Terrone, C.
    Bauckneht, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S218 - S218
  • [40] INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer
    King, Martin T.
    Wise, David R.
    Scala, Lawrence M.
    Mariados, Neil M.
    Whitbeck, Amanda
    Pomerantz, Mark
    Bober, Sharon
    Davicioni, Elai
    Bubley, Glenn
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345